Fully funded by 
Content independently selected
Data from the phase 3 KLASS-01 randomized trial.
No PFS benefit in patients receiving cisplatin plus fluoropyrimidine chemotherapy.
Clinical characteristics could guide strategy.
Presence can help determine surgical strategy.
The role of continuing perioperative chemotherapy post-surgery in oesophageal or gastroesophageal junction adenocarcinoma
Nomogram of CT phenotypes and Lauren type shows excellent prognostic value.
Findings support standard 1-year treatment duration.
TAGS phase 3 study of patients with heavily pretreated metastatic gastric cancer.
The new quality standards state that the results of F‑18 FDG PET‑CT scans should be reported within one week of the decision to scan
Cancer Research UK announces the first UK trial of breath biopsy technology to detect multiple cancer types.
Chinese medicine delivers results in meta-analysis.
NLR increase associated with nearly 7 times worse OS.
Pooled analysis of data from RAINBOW and REGARD phase 3 trials.
Herzuma approval follows that of Ogivri.
Study builds on evidence from 1-, 2-, and 3-year trials.
Overall cancer risk boosted by 28%.
Only 47% of patients undergo radical cholecystectomy with regional lymphadenectomy.
